Understanding intravascular delivery of adenovirus gene therapy vectors
Andrew Byrnes, PhD
Chief, Gene Transfer and Immunogenicity Branch Division of Cellular and Gene Therapies, FDA
Dr. Byrnes is Chief of the Gene Transfer and Immunogenicity Branch in the Division of Cellular and Gene Therapies at FDA’s Center for Biologics Evaluation and Research. Dr. Byrnes joined the FDA in 2000. He is a principal investigator and reviews manufacturing of gene therapies, cell therapies and other investigational biologics. Dr. Byrnes has a background in virology and gene therapy, and his laboratory research focuses on adenovirus gene therapy in rodent models. Research interests include vector biodistribution, clearance of vector by the liver, interactions of virions with natural antibodies and complement, and innate immune reactions to viral vectors.
Host: Julia Davydova, MD, PhD